HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa.

AbstractOBJECTIVE:
Pericardial involvement is a common feature in different neoplastic diseases, having a strong influence on the natural history of the disease and on the quality of life of the patients. This study was performed in order to investigate the long-term effects of intracavitary treatment with thiotepa in the reduction of pericardial effusion (PE) recurrences.
DESIGN:
Prospective controlled intervention study.
SETTING:
European Institute of Oncology, Milan, Italy.
PATIENTS:
We studied 33 patients, 15 men and 18 women, with malignant PE, who were affected by breast cancer (11 patients), lung cancer (16 patients), microcytoma (4 patients), endometrial cancer (1 patients), and melanoma (1 patient).
INTERVENTION:
All patients with large PE, with or without cardiac tamponade, underwent percutaneous pericardiocentesis (PC) under echocardiographic monitoring. Patients with neoplastic cells in drained fluid were considered to be eligible for treatment. After drainage, the catheter was maintained in the pericardial sac for the instillation of a sclerosing, alkylating antiblastic agent (thiotepa) on days 1, 3, and 5 after the PC (15 mg at each step).
RESULTS:
No procedure-related complications or side effects were observed. Two patients died because of disease progression, without PE evidence. No PE occurred in the remaining patients during the first month. Three recurrences occurred (9.1%), requiring additional PC and intrapericardial treatment. The median survival time was 115 days (range, 22 to 1,108 days) in the overall population, and 272 days in patients with breast cancer.
CONCLUSIONS:
Intrapericardial treatment with thiotepa carries a minimal risk and is a repeatable procedure that can dramatically increase quality of life, or even can improve survival and the natural history of disease in cancer patients.
AuthorsAlessandro Martinoni, Carlo Maria Cipolla, Daniela Cardinale, Maurizio Civelli, Giuseppina Lamantia, Marco Colleoni, Cesare Fiorentini
JournalChest (Chest) Vol. 126 Issue 5 Pg. 1412-6 (Nov 2004) ISSN: 0012-3692 [Print] United States
PMID15539706 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Review)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Thiotepa
Topics
  • Antineoplastic Agents, Alkylating (administration & dosage)
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Instillation, Drug
  • Male
  • Neoplasms (complications, drug therapy)
  • Pericardial Effusion (etiology, therapy)
  • Pericardiocentesis
  • Prospective Studies
  • Thiotepa (administration & dosage)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: